Knockdown of PTHR1 in osteosarcoma cells decreases invasion and growth and increases tumor differentiation in vivo
PWM Ho, A Goradia, MR Russell, AM Chalk, KM Milley, EK Baker, JA Danks, JL Slavin, M Walia, B Crimeen-Irwin, RA Dickins, TJ Martin, CR Walkley
Oncogene | NATURE PUBLISHING GROUP | Published : 2015
We thank the SVH BioResources Centre; P Kocovski and S Taylor for technical assistance, L Purton and J Heierhorst for comments and discussion. This work was supported by grants from the National Health and Medical Research Council of Australia (NHMRC; to CRW and CRW/TJM); Cancer Council of Victoria (to CRW and EKB); NHMRC Career Development Award (CRW); Cure Cancer Australia Foundation Fellowship (EKB); in part by the Victorian State Government Operational Infrastructure Support Program (to St. Vincent's Institute). CRW is the Philip Desbrow Senior Research Fellow of the Leukaemia Foundation. The authors thank Chugai Pharmaceutical Company for providing the alpha-PTHrP neutralizing antibody; The Structural Genomics Consortium for generously providing GSK343 and UNC1999.